Halozyme Therapeutics, Inc. $HALO Shares Acquired by Swedbank AB

Swedbank AB lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 162,062 shares of the biopharmaceutical company’s stock after acquiring an additional 14,900 shares during the period. Swedbank AB’s holdings in Halozyme Therapeutics were worth $10,907,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Root Financial Partners LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter valued at $25,000. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the last quarter. Richardson Financial Services Inc. boosted its stake in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 198 shares during the last quarter. Clearstead Advisors LLC boosted its stake in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 265 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter valued at $52,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $64.12 on Friday. The business’s 50-day moving average price is $65.86 and its 200 day moving average price is $68.59. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22. The company has a market capitalization of $7.60 billion, a PE ratio of 25.75, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter last year, the company posted $1.26 earnings per share. The business’s quarterly revenue was up 51.6% compared to the same quarter last year. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the transaction, the director directly owned 38,498 shares in the company, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $49,322,187.20. This trade represents a 2.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 90,482 shares of company stock worth $6,073,942. 2.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on HALO shares. HC Wainwright increased their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Finally, Benchmark increased their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $79.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.